|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Massagué J: TGF-beta signal transduction.
Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kitisin K, Saha T, Blake T, Golestaneh N,
Deng M, Kim C, Tang Y, Shetty K, Mishra B and Mishra L: TGF-Beta
signaling in development. Sci STKE. 2007.cm1:2007.
|
|
7
|
Kim WS, Park C, Jung YS, Kim HS, Han J,
Park CH, Kim K, Kim J, Shim YM and Park K: Reduced transforming
growth factor-beta type II receptor (TGF-beta RII) expression in
adeno-carcinoma of the lung. Anticancer Res. 19A:301–306. 1999.
|
|
8
|
Park C, Kim WS, Choi Y, Kim H and Park K:
Effects of transforming growth factor beta (TGF-beta) receptor on
lung carcinogenesis. Lung Cancer. 38:143–147. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
David CJ, Huang YH, Chen M, Su J, Zou Y,
Bardeesy N, Iacobuzio-Donahue CA and Massagué J: TGF-β tumor
suppression through a lethal EMT. Cell. 164:1015–1030. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gregory PA, Bracken CP, Smith E, Bert AG,
Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, et al:
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates
establishment and maintenance of epithelial-mesenchymal transition.
Mol Biol Cell. 22:1686–1698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014.PubMed/NCBI
|
|
14
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Principe DR, Doll JA, Bauer J, Jung B,
Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β:
Duality of function between tumor prevention and carcinogenesis. J
Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar
|
|
17
|
Mlcochova J, Faltejskova P, Nemecek R,
Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway
in colorectal cancer. J Cancer Res Clin Oncol. 139:1615–1624. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmidt A and Küppers R: Role of microRNAs
in B cell leukemias and lymphomas. Curr Mol Med. 14:580–597. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi X, Zhan L, Xiao C, Lei Z, Yang H, Wang
L, Zhao J and Zhang HT: miR-1238 inhibits cell proliferation by
targeting LHX2 in non-small cell lung cancer. Oncotarget.
6:19043–19054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mirzamohammadi F, Papaioannou G and
Kobayashi T: MicroRNAs in cartilage development, homeostasis, and
disease. Curr Osteoporos Rep. 12:410–419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang JA: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015.PubMed/NCBI
|
|
24
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lebanony D, Benjamin H, Gilad S, Ezagouri
M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, et
al: Diagnostic assay based on hsa-miR-205 expression distinguishes
squamous from nonsquamous non-small-cell lung carcinoma. J Clin
Oncol. 27:2030–2037. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cai J, Fang L, Huang Y, Li R, Yuan J, Yang
Y, Zhu X, Chen B, Wu J and Li M: miR-205 targets PTEN and PHLPP2 to
augment AKT signaling and drive malignant phenotypes in non-small
cell lung cancer. Cancer Res. 73:5402–5415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang H, Wang L, Zhao J, Chen Y, Lei Z, Liu
X, Xia W, Guo L and Zhang HT: TGF-β-activated SMAD3/4 complex
transcriptionally upregulates N-cadherin expression in non-small
cell lung cancer. Lung Cancer. 87:249–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hesling C, Fattet L, Teyre G, Jury D,
Gonzalo P, Lopez J, Vanbelle C, Morel AP, Gillet G, Mikaelian I, et
al: Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary
epithelial cells. EMBO Rep. 12:665–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng H, Fertig EJ, Ozawa H, Hatakeyama H,
Howard JD, Perez J, Considine M, Thakar M, Ranaweera R, Krigsfeld
G, et al: Decreased SMAD4 expression is associated with induction
of epithelial-to-mesenchymal transition and cetuximab resistance in
head and neck squamous cell carcinoma. Cancer Biol Ther.
16:1252–1258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang W, Jin Y, Yuan Y, Bai C, Wu Y, Zhu H
and Lu S: Validation and target gene screening of hsa-miR-205 in
lung squamous cell carcinoma. Chin Med J (Engl). 127:272–278.
2014.
|
|
32
|
Du L, Schageman JJ, Irnov, Girard L,
Hammond SM, Minna JD, Gazdar AF and Pertsemlidis A: MicroRNA
expression distinguishes SCLC from NSCLC lung tumor cells and
suggests a possible pathological relationship between SCLCs and
NSCLCs. J Exp Clin Cancer Res. 29:752010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Larzabal L, de Aberasturi AL, Redrado M,
Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM and Calvo A:
TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205
activity to promote metastasis. Br J Cancer. 110:764–774. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Asselin-Paturel C, Echchakir H, Carayol G,
Gay F, Opolon P, Grunenwald D, Chouaib S and Mami-Chouaib F:
Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression
in tumor, TIL and PBL of non-small cell lung cancer patients. Int J
Cancer. 77:7–12. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bennett WP, el-Deiry WS, Rush WL, Guinee
DG Jr, Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A,
Travis WD, et al: p21waf1/cip1 and transforming growth factor beta
1 protein expression correlate with survival in non-small cell lung
cancer. Clin Cancer Res. 4:1499–1506. 1998.PubMed/NCBI
|
|
36
|
Akhurst RJ and Balmain A: Genetic events
and the role of TGF beta in epithelial tumour progression. J
Pathol. 187:82–90. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han G, Lu SL, Li AG, He W, Corless CL,
Kulesz-Martin M and Wang XJ: Distinct mechanisms of
TGF-beta1-mediated epithelial-to-mesenchymal transition and
metastasis during skin carcinogenesis. J Clin Invest.
115:1714–1723. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hahn SA, Schutte M, Hoque AT, Moskaluk CA,
da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban
RH, et al: DPC4, a candidate tumor suppressor gene at human
chromosome 18q21.1. Science. 271:350–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bardeesy N, Cheng KH, Berger JH, Chu GC,
Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, et
al: Smad4 is dispensable for normal pancreas development yet
critical in progression and tumor biology of pancreas cancer. Genes
Dev. 20:3130–3146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vincent T, Neve EP, Johnson JR, Kukalev A,
Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL,
et al: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes
TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol.
11:943–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar
|
|
42
|
Kumarswamy R, Mudduluru G, Ceppi P,
Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H:
MicroRNA-30a inhibits epithelial-to-mesenchymal transition by
targeting Snai1 and is downregulated in non-small cell lung cancer.
Int J Cancer. 130:2044–2053. 2012. View Article : Google Scholar
|
|
43
|
Qiao P, Li G, Bi W, Yang L, Yao L and Wu
D: microRNA-34a inhibits epithelial mesenchymal transition in human
cholangio-carcinoma by targeting Smad4 through transforming growth
factor-beta/Smad pathway. BMC Cancer. 15:4692015. View Article : Google Scholar
|
